Protein complexes for antigen binding and methods of use

Patent metadata

Field	Value
Publication number	US-9518132-B2
Application number	US-201113883282-A
Country	US
Kind code	B2
Filing date	Nov 9, 2011
Priority date	Nov 9, 2010
Publication date	Dec 13, 2016
Grant date	Dec 13, 2016

Abstract

Provided herein in certain embodiments are polypeptide complexes capable of binding to an antigen. Pharmaceutical compositions, method of using the polypeptide complexes are also provided.

First claim

We claim:

1. A polypeptide complex comprising:
a first polypeptide comprising from N-terminus to C-terminus: a first antigen-binding domain, a first protein monomer, a first thiol residue-containing peptide linker and a second antigen-binding domain, and
a second polypeptide comprising from N-terminus to C-terminus: a third antigen-binding domain, a second protein monomer, a second thiol residue-containing peptide linker and a fourth antigen-binding domain,
wherein the first protein monomer forms a dimer with the second protein monomer, and each of the first and the second protein monomers comprises a CH3 domain from an immunoglobulin;
wherein the first peptide linker and the second peptide linker form a disulfide bond, and each of the first thiol peptide linker and the second peptide linker independently comprises a sequence selected from the group consisting of: SEQ ID NO: 68, SEQ ID NO: 69, and SEQ ID NO: 70;
wherein the first antigen-binding domain and the third antigen-binding domain are capable of binding to a first antigen, and the second antigen-binding domain and the fourth antigen-binding domain are capable of binding to a second antigen, and one of the first and the second antigens is human CD3 and the other is human EpCAM or human CD19, and
wherein each of the first, second, third, and fourth antigen-binding domains is independently selected from the group consisting of VH, VL, Fab, and scFv.

2. The polypeptide complex of claim 1 wherein the disulfide bond reduces the simultaneous binding of the first antigen-binding domain and the second antigen-binding domain to the first antigen, and of the third antigen-binding domain and the fourth antigen-binding domain to the second antigen.

3. The polypeptide complex of claim 1 wherein the first protein monomer is the same as the second protein monomer.

4. The polypeptide complex of claim 1 wherein the first antigen-binding domain is the same as the second antigen-binding domain, and/or the third antigen-binding domain is the same as the fourth antigen-binding domain.

5. The polypeptide complex of claim 1 wherein the first protein monomer and/or the second protein monomer further comprise a CH2 domain from the immunoglobulin and the C-terminal of the CH2 domain is covalently linked to the N-terminal of the CH3 domain.

6. The polypeptide complex of claim 1 wherein the immunoglobulin is selected from the group consisting of IgA, IgD, IgE, IgG, and IgM.

7. The polypeptide complex of claim 1 wherein the first antigen-binding domain or the second antigen-binding domain is Fab comprising a first light chain fragment which is disulfidely bonded to a first heavy chain fragment.

8. The polypeptide complex of claim 1 wherein the first antigen-binding domain or the second antigen-binding domain is Fab comprising a second heavy chain fragment which is disulfidely bonded to a second light chain fragment.

9. A composition comprising the polypeptide complex of any of claims 1 , 2 - 4 , 5 , 6 , 7 - 8 and one or more conjugates, wherein the polypeptide complex is linked to the one or more conjugates.

10. A pharmaceutical composition comprising the polypeptide complex of any of claims 1 , 2 - 4 , 5 , 6 , 7 - 8 , and a pharmaceutically acceptable carrier.

11. The polypeptide complex of claim 1 wherein the first and second antigen-binding domains are Fab and the third and fourth binding domains are scFv.

12. The polypeptide complex of claim 1 wherein the third and fourth antigen-binding domains are scFv and the first and second binding domains are Fab.

13. The polypeptide complex of claim 1 wherein the first antigen is human EpCAM or human CD19, and the second antigen is human CD3.

14. The polypeptide complex of claim 1 wherein the first antigen is human CD3, and the second antigen is human EpCAM or human CD19.

15. The polypeptide complex of claim 1 wherein the first antigen-binding domain is anti-CD3 Fab, and the second antigen-binding domain is anti-CD19 scFv.

16. The polypeptide complex of claim 1 wherein the first antigen-binding domain is anti-CD3 Fab, and the second antigen-binding domain is anti-EpCAM scFv.

Assignees

• Li Zijuan
• Wu Chun
• Bao Jun
• Chen Bo
• Altimab Therapeutics Inc

Inventors

• Li Zijuan
• Wu Chun
• Bao Jun
• Chen Bo

Classifications

• C07K2317/31

  multispecific · CPC title

• C07K16/2809

  against the T-cell receptor (TcR)-CD3 complex · CPC title

• C07K2317/30

  characterized by aspects of specificity or valency · CPC title

• G01N33/6854

  Immunoglobulins · CPC title

• C07K16/00 Primary

  Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies · CPC title